Sysmex Corporation celebrated the 50th anniversary of its establishment on February 20, 2018. We offer our heartfelt appreciation for the support of our customers and all other stakeholders since the time of our establishment in 1968.
Hamburg, Germany, 2018.01.16 – Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data from an abstract of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test. The […]
Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation signed a distribution agreement with genedrive plc the near patient molecular diagnostics company, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region. This is genedrive’s second agreement signed with a subsidiary of Sysmex Corporation, a world leader in clinical […]
Colorectal cancer is the second most commonly occurring cancer in Malaysia (Malaysian National Cancer Registry Report 2007-2011). A new liquid biopsy testing to monitor the progression of metastatic cases of colorectal cancer is now available at Pantai Premier Pathology, Malaysia. The new liquid biopsy testing allows oncologists and surgeons to examine a ‘snapshot’ of the […]
The Dow Jones Sustainability Indexes are developed through collaboration between S&P Dow Jones Indices of the United States and Robeco SAM, a Swiss research specialist in the area of socially responsible investment. This year Sysmex has been selected for inclusion in the DJSI World for the second consecutive year.
Creating a System for Operating Mobile Pharmacies as a Disaster Response Measure – Sysmex Corporation, the Hyogo Pharmaceutical Society and Shinkai Transport Systems, Ltd. announce the signing of an agreement to cooperate on disaster relief activities, aimed at operating mobile pharmacies in times of disaster.
In order to continue supporting the initiatives of the GHIT Fund, which aims to assist in the application of Japanese technological innovation to healthcare in developing countries, we will be extending our provision of donations for a five-year period from 2018. By participating in the GHIT Fund, we will move forward with initiatives to develop […]
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has opened a new R&D facility within its Kawasaki INnovation Gateway at SKYFRONT in the city of Kawasaki, Kanagawa Prefecture, to pursue R&D in bioinformatics, a key technology toward the realization of personalized medicine.
Sysmex Corporation has reached an agreement with Oxford Gene Technology IP Limited (“OGT”) to acquire all shares in OGT. Through this move, Sysmex aims to obtain OGT’s business and expertise in the cytogenetics1 domain and its reagent development capabilities used in next-generation sequencers (NGSs)2, thereby reinforcing its base in the life science business.
Sysmex Corporation has received the Invention Award in the National Commendation for Invention1, sponsored by the Japan Institute of Invention and Innovation, for its hematology analyzers that enables the rapid evaluation of the effects of administering iron preparations. The award ceremony is scheduled to be held in Tokyo on Monday, June 12.
Sysmex New Zealand has been synonymous with the Delphic and Eclair suite of lab and clinical IT solutions for over three decades. The Sysmex New Zealand team are excited to announce, effective 1st May we will be managing the direct sales and support of the Sysmex Urinalysis instrument portfolio.
Sysmex New Zealand has appointed a new senior management team. James Webster has stepped aside as Sysmex New Zealand CEO to focus his full attention on his role as Sysmex Australia CEO. Assuming the position of Sysmex New Zealand CEO is Arjit Bhana, formerly the company’s General Manager.